Takayuki Nose1, Yuki Otani2, Shuuji Asahi3, Iwao Tsukiyama4, Takushi Dokiya5, Toshiaki Saeki6, Ichirou Fukuda5, Hiroshi Sekine5, Naoto Shikama5, Yu Kumazaki5, Takao Takahashi6, Ken Yoshida7, Tadayuki Kotsuma7, Norikazu Masuda8, Eisaku Yoden9, Kazutaka Nakashima10, Taisei Matsumura11, Shino Nakagawa12, Seiji Tachiiri13, Yoshio Moriguchi14, Jun Itami15, Masahiko Oguchi16. 1. Department of Radiation Oncology, Nippon Medical School Tama Nagayama Hospital, 1-7-1 Nagayama, Tama, Tokyo, 206-8512, Japan. nose-takayuki@nms.ac.jp. 2. Department of Radiology, Kaizuka City Hospital, Kaizuka, Japan. 3. Departments of Surgery, Aidu Chuo Hospital, Aiduwakamatsu, Japan. 4. Departments of Radiology, Aidu Chuo Hospital, Aiduwakamatsu, Japan. 5. Departments of Radiation Oncology, International Medical Center, Saitama Medical University, Hidaka, Japan. 6. Departments of Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Japan. 7. Departments of Radiation Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan. 8. Departments of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan. 9. Departments of Radiation Oncology, Kawasaki Medical School, Kurashiki, Japan. 10. Departments of Surgery, Kawasaki Medical School, Kurashiki, Japan. 11. Departments of Radiology, National Hospital Organization, National Kyushu Medical Center, Fukuoka, Japan. 12. Departments of Surgery, National Hospital Organization National Kyushu Medical Center, Fukuoka, Japan. 13. Departments of Radiation Oncology, Kyoto City Hospital, Kyoto, Japan. 14. Departments of Breast Surgery, Kyoto City Hospital, Kyoto, Japan. 15. Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan. 16. Department of Radiation Oncology, Cancer Institute Hospital, The Japanese Foundation for Cancer Research, Tokyo, Japan.
Abstract
BACKGROUND: A Japanese prospective multi-institutional feasibility study on accelerated partial breast irradiation using interstitial brachytherapy was performed. The first clinical results were reported with a median follow-up of 26 months. PATIENTS AND METHODS: Forty-six female breast cancer patients with positive hormone receptors and tumors ≤3 cm, pN0M0, completed the protocol treatment. After breast-conserving surgery and histological confirmation of negative surgical margins and pN0, brachytherapy applicators were implanted either postoperatively (n = 45) or intraoperatively (n = 1). High-dose-rate brachytherapy of 36 Gy/6 fractions was delivered. All clinical data were prospectively collected using case report forms and the Common Terminology Criteria for Adverse Events ver.3.0. RESULTS: At the median follow-up of 26 months, no breast cancer recurrence of any type was observed. Sequelae ≥G2 were dermatitis (G2, 7 %), fibrosis (G2, 11 %; G3, 4 %), fracture (G2, 2 %), pain (G2, 7 %; G3, 2 %), and soft tissue necrosis (G2, 6 %). Cosmetic outcomes evaluated by excellent/good scores were 100 % at pre-therapy (n = 46), 94 % at 12 months (n = 46), and 81 % at 24 months (n = 36), respectively. CONCLUSIONS: Disease control and sequelae were satisfactory due to the strict eligibility and protocol-defined treatment parameters. The cosmetic outcomes were comparable to those of previous Japanese breast-conserving therapy series.
BACKGROUND: A Japanese prospective multi-institutional feasibility study on accelerated partial breast irradiation using interstitial brachytherapy was performed. The first clinical results were reported with a median follow-up of 26 months. PATIENTS AND METHODS: Forty-six female breast cancerpatients with positive hormone receptors and tumors ≤3 cm, pN0M0, completed the protocol treatment. After breast-conserving surgery and histological confirmation of negative surgical margins and pN0, brachytherapy applicators were implanted either postoperatively (n = 45) or intraoperatively (n = 1). High-dose-rate brachytherapy of 36 Gy/6 fractions was delivered. All clinical data were prospectively collected using case report forms and the Common Terminology Criteria for Adverse Events ver.3.0. RESULTS: At the median follow-up of 26 months, no breast cancer recurrence of any type was observed. Sequelae ≥G2 were dermatitis (G2, 7 %), fibrosis (G2, 11 %; G3, 4 %), fracture (G2, 2 %), pain (G2, 7 %; G3, 2 %), and soft tissue necrosis (G2, 6 %). Cosmetic outcomes evaluated by excellent/good scores were 100 % at pre-therapy (n = 46), 94 % at 12 months (n = 46), and 81 % at 24 months (n = 36), respectively. CONCLUSIONS: Disease control and sequelae were satisfactory due to the strict eligibility and protocol-defined treatment parameters. The cosmetic outcomes were comparable to those of previous Japanese breast-conserving therapy series.
Entities:
Keywords:
Accelerated partial breast irradiation; Brachytherapy; Breast cancer; Radiotherapy
Authors: Javier Anchuelo Latorre; Piedad Galdós; Lucía Alonso Buznego; Ana García Blanco; Juan Cardenal; María Ferri; Iván Díaz de Cerio; Elisabet Arrojo; Nicolás Sierrasesúmaga; Mónica González Noriega; Ana De Juan Ferré; Rosa Fabregat; Samuel Ruíz; Pedro J Prada Journal: J Contemp Brachytherapy Date: 2018-02-28